Current Report Filing (8-k)
September 05 2018 - 05:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 5, 2018
NEUROTROPE, INC.
(Exact name of registrant as specified
in its charter)
Nevada
|
001-38045
|
46-3522381
|
(State or other
jurisdiction of
incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification
Number)
|
1185 Avenue of the Americas, 3
rd
Floor
New York, New York 10036
(Address of principal executive offices,
including ZIP code)
(973) 242-0005
(Registrant’s telephone number,
including area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company.
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01 Other Events.
On September 5, 2018, Neurotrope, Inc. (the “Company”)
announced a collaboration with The Nemours / Alfred I. duPont Hospital for Children (“Nemours”) to initiate a clinical
trial in children with Fragile X Syndrome (“Fragile X”). The planned protocol for the trial will dose Fragile X patients
between the ages of 8 and less than 18, using a dosing regimen similar to the dosing regimen used in the Company’s completed
Phase 2 trial involving patients with Alzheimer’s disease.
In addition to the primary
objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as
anxiety, repetitive behavior, executive functioning, and social behavior.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
NEUROTROPE, INC.
|
|
|
|
Dated: September 5, 2018
|
By:
|
/s/ Robert Weinstein
|
|
|
Name: Robert Weinstein
|
|
|
Title: Chief Financial Officer, Executive Vice President, Secretary and Treasurer
|
NextTrip (NASDAQ:NTRP)
Historical Stock Chart
From Feb 2024 to Mar 2024
NextTrip (NASDAQ:NTRP)
Historical Stock Chart
From Mar 2023 to Mar 2024